Adriano Chio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2193235/publications.pdf

Version: 2024-02-01

467	37,056	3531 90	4432 172
papers	citations	h-index	g-index

486	486	486	24340
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain, 2022, 145, 276-284.	7.6	22
2	Amyotrophic lateral sclerosis caregiver burden and patientsâ€™ quality of life during COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 146-148.	1.7	15
3	Acute and chronic synaptic pathology in multiple sclerosis gray matter. Multiple Sclerosis Journal, 2022, 28, 369-382.	3.0	14
4	What is amyotrophic lateral sclerosis prevalence?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 203-208.	1.7	8
5	Italian adaptation of the Beaumont Behavioral Inventory (BBI): psychometric properties and clinical usability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 81-86.	1.7	10
6	Tailoring patientsâ€™ enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 108-115.	1.7	1
7	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
8	Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine, 2022, 75, 103795.	6.1	32
9	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2242-2250.	6.4	9
10	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
11	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
12	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, 395.	3.3	7
13	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	36
14	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain, 2022, 145, 1207-1210.	7.6	21
15	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. Computer Methods and Programs in Biomedicine, 2022, 216, 106681.	4.7	3
16	AIM in Amyotrophic Lateral Sclerosis. , 2022, , 1691-1703.		0
17	Incidence of amyotrophic lateral sclerosis in Sardinia, Italy: ageâ€“sex interaction and spatialâ€“temporal variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 585-591.	1.7	7
18	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38

#	Article	IF	Citations
19	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
20	The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 527-531.	1.7	10
21	Brain¹⁸fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis withTARDBPmutations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1021-1023.	1.9	4
22	Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. Journal of Neurology, 2022, 269, 3858-3878.	3.6	7
23	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. The Lancet Digital Health, 2022, 4, e359-e369.	12.3	19
24	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 480-493.	10.2	124
25	Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 465-479.	10.2	130
26	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 424-429.	1.7	2
27	Social cognition deficits in amyotrophic lateral sclerosis: A pilot crossâ€sectional populationâ€based study. European Journal of Neurology, 2022, 29, 2211-2219.	3.3	8
28	Respiratory support in a population-based ALS cohort: demographic, timing and survival determinants. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1024-1026.	1.9	8
29	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 Mutation. Neurology, 2021, 96, e141-e152.	1.1	17
30	Atypical motor neuron disease with bent spine clinical onset and long survival carrying C9orf72 expansion. Neurological Sciences, 2021, 42, 353-355.	1.9	1
31	Broadening the clinical spectrum of FUS mutations: a case with monomelic amyotrophy with a late progression to amyotrophic lateral sclerosis. Neurological Sciences, 2021, 42, 1207-1209.	1.9	3
32	Brain metabolic changes across Kingâ€™s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1124-1133.	6.4	10
33	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€FDGâ€positron emission tomography stud. European Journal of Neurology, 2021, 28, 745-753.	3.3	10
34	Metabolic brain changes across different levels of cognitive impairment in ALS: a¹⁸F-FDG-PET study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 357-363.	1.9	14
35	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
36	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 1181-1187.	3.3	4

#	Article	IF	Citations
37	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. Neurology, 2021, 96, e600-e609.	1.1	23
38	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. Neurobiology of Aging, 2021, 98, 205-213.	3.1	15
39	Sleep in ALS: more than discomfort or respiratory breathing disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 5-5.	1.9	2
40	Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 165-171.	1.9	20
41	Validation of the Italian version of self-administered ALSFRS-R scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 151-153.	1.7	9
42	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 308-311.	1.7	27
43	Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Science Advances, 2021, 7, .	10.3	59
44	Stapedial Reflex: A Possible Novel Biomarker of Early Bulbar Involvement in Amyotrophic Lateral Sclerosis Patients. Audiology and Neuro-Otology, 2021, 26, 353-360.	1.3	0
45	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2021, 144, 3710-3726.	7.6	13
46	Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1017-1019.	1.9	4
47	The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurological Sciences, 2021, 42, 1377-1387.	1.9	18
48	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
49	Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum. Journal of Neurology, 2021, 268, 3766-3776.	3.6	12
50	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-9.	1.7	2
51	The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain, 2021, 144, 2635-2647.	7.6	33
52	Nature meets nurture in amyotrophic lateral sclerosis. Lancet Neurology, The, 2021, 20, 332-333.	10.2	0
53	Highlighting the clinical potential of HTT repeat expansions in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 1947-1948.	8.1	3
54	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 33-39.	1.7	8

#	Article	IF	Citations
55	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. Neurobiology of Aging, 2021, 103, 130.e1-130.e7.	3.1	7
56	Untangling the knot: Lifetime physical exercise and amyotrophic lateral sclerosis. EBioMedicine, 2021, 69, 103438.	6.1	2
57	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-7.	1.7	1
58	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2021, 16, 52.	10.8	19
59	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
60	Developments in the assessment of non-motor disease progression in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 1419-1440.	2.8	10
61	GBA variants influence cognitive status in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327426.	1.9	3
62	Correlations between measures of ALS respiratory function: is there an alternative to FVC?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 495-504.	1.7	2
63	A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discovery, 2021, 7, 4.	4.7	36
64	HMSN-P associated with TFG P.PRO285LEU variant in an Italian family. Journal of the Neurological Sciences, 2021, 429, 119383.	0.6	0
65	A different cognitive and behavioral profile in ALS patients with or without C9orf72 expansion. Journal of the Neurological Sciences, 2021, 429, 117745.	0.6	0
66	Advances in the genetics of MND. Journal of the Neurological Sciences, 2021, 429, 117983.	0.6	0
67	Cortical and subcortical damage: Differences between C9orf72 ALS mutation carriers and wild-type ALS patients. Journal of the Neurological Sciences, 2021, 429, 117763.	0.6	0
68	What is amyotrophic lateral sclerosis prevalence?. Journal of the Neurological Sciences, 2021, 429, 118242.	0.6	0
69	Brain 18F-FDG-PET signature of ALS with SOD1 and TARDBP mutations. Journal of the Neurological Sciences, 2021, 429, 119396.	0.6	0
70	The role of anxiety as a prognostic factor in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117743.	0.6	0
71	SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Communications, 2021, 3, fcab236.	3.3	14
72	Validation of the Italian version of the Rasch-built overall amyotrophic lateral sclerosis disability scale (roads). Journal of the Neurological Sciences, 2021, 429, 119384.	0.6	0

#	Article	IF	Citations
73	Respiratory domain of ALSFRS-R scale increases arterial blood gas analysisâ€™ sensitivity in assessing pulmonary function in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117705.	0.6	0
74	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
75	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 5-14.	1.7	133
76	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 33-39.	1.9	20
77	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 291-297.	1.9	18
78	Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. Neurology, 2020, 95, 1015-1018.	1.1	19
79	The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. Brain Sciences, 2020, 10, 650.	2.3	8
80	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Communications, 2020, 2, fcaa142.	3.3	55
81	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.7	20
82	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1001-1003.	1.9	14
83	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
84	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. NeuroImage: Clinical, 2020, 27, 102312.	2.7	7
85	Exploiting mutual information for the imputation of static and dynamic mixed-type clinical data with an adaptive k-nearest neighbours approach. BMC Medical Informatics and Decision Making, 2020, 20, 174.	3.0	12
86	Structural and functional brain connectome in motor neuron diseases. Neurology, 2020, 95, e2552-e2564.	1.1	34
87	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	9.0	45
88	Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 373-379.	1.7	40
89	Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Research, 2020, 10, 23.	2.5	17
90	Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 436-437.	1.9	25

#	Article	IF	Citations
91	The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 999-1000.	1.9	13
92	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
93	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1615-1621.	3.6	18
94	ALS phenotype is influenced by age, sex, and genetics. Neurology, 2020, 94, e802-e810.	1.1	99
95	Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology, 2020, 167, 107986.	4.1	75
96	Plateaus in amyotrophic lateral sclerosis progression: results from a populationâ€based cohort. European Journal of Neurology, 2020, 27, 1397-1404.	3.3	11
97	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. Journal of Clinical Neuroscience, 2020, 75, 223-225.	1.5	3
98	A novel p.N66T mutation in exon 3 of the SOD1 gene: report of two families of ALS patients with early cognitive impairment. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 296-300.	1.7	6
99	G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open, 2020, 10, e034049.	1.9	7
100	The NGS technology for the identification of genes associated with the ALS. A systematic review. European Journal of Clinical Investigation, 2020, 50, e13228.	3.4	16
101	The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	8
102	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
103	Prognostic power of the human psoas muscles FDG metabolism in amyotrophic lateral sclerosis. , 2020, , .		0
104	Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	1
105	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. European Neurology, 2020, 83, 626-629.	1.4	1
106	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 11-19.	1.9	26
107	Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohort. Neurological Sciences, 2019, 40, 2537-2540.	1.9	7
108	Associations of Electric Shock and Extremely Low-Frequency Magnetic Field Exposure With the Risk of Amyotrophic Lateral Sclerosis. American Journal of Epidemiology, 2019, 188, 796-805.	3.4	20

#	Article	IF	Citations
109	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Scientific Reports, 2019, 9, 690.	3.3	46
110	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Frontiers in Neuroscience, 2019, 13, 485.	2.8	35
111	Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open, 2019, 9, e028486.	1.9	44
112	Alcohol Consumption and the Risk of Amyotrophic Lateral Sclerosis. , 2019, , 207-216.		2
113	A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression. BMC Bioinformatics, 2019, 20, 118.	2.6	20
114	Multicentre, population-based, caseâ€“control study of particulates, combustion products and amyotrophic lateral sclerosis risk. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 854-860.	1.9	17
115	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
116	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 5931.	3.3	16
117	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. Journal of Neurology, 2019, 266, 1633-1642.	3.6	25
118	Physiciansâ€™ attitudes toward end-of-life decisions in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 74-81.	1.7	16
119	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
120	Validation of the revised classification of cognitive and behavioural impairment in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 734-739.	1.9	17
121	Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology, 2019, 93, e984-e994.	1.1	115
122	Divining progression in Parkinson disease with a blood test. Neurology, 2019, 93, 471-472.	1.1	1
123	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 155-164.	10.2	63
124	Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 666-673.	1.9	73
125	Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1117-1131.	6.4	18
126	Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. European Journal of Neurology, 2019, 26, 306-312.	3.3	8

#	Article	IF	Citations
127	Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. European Journal of Neurology, 2018, 25, 861-868.	3.3	29
128	Multicentre, cross-cultural, population-based, caseâ€“control study of physical activity as risk factor for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 797-803.	1.9	45
129	Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a populationâ€based cluster analysis. European Journal of Neurology, 2018, 25, 756-761.	3.3	9
130	Amyotrophic lateral sclerosis and food intake. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 267-274.	1.7	29
131	NADPH oxidases 2 activation in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2018, 49, 110-111.	2.2	7
132	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
133	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
134	Network Analysis Identifies Disease-Specific Pathways for Parkinsonâ€™s Disease. Molecular Neurobiology, 2018, 55, 370-381.	4.0	23
135	Common polymorphisms of chemokine (Câ€X3â€C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A populationâ€based study. Muscle and Nerve, 2018, 57, 212-216.	2.2	25
136	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.7	26
137	The role of preâ€morbid diabetes on developing amyotrophic lateral sclerosis. European Journal of Neurology, 2018, 25, 164-170.	3.3	45
138	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
139	Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurology, The, 2018, 17, 94-102.	10.2	432
140	Gâ€quadruplexâ€binding small molecules ameliorate C9orf72 <scp>FTD</scp> / <scp>ALS</scp> pathology inÂvitro and inÂvivo. EMBO Molecular Medicine, 2018, 10, 22-31.	6.9	178
141	Rapamycin treatment for amyotrophic lateral sclerosis. Medicine (United States), 2018, 97, e11119.	1.0	96
142	Gene-Environment-Time Interactions in Neurodegenerative Diseases: Hypotheses and Research Approaches. Annals of Neurosciences, 2018, 25, 261-267.	1.7	31
143	Mice with endogenous <scp>TDP</scp> â€43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO Journal, 2018, 37, .	7.8	129
144	Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821.	2.5	22

#	Article	IF	Citations
145	The multistep hypothesis of ALS revisited. Neurology, 2018, 91, e635-e642.	1.1	146
146	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain, 2018, 141, 2272-2279.	7.6	33
147	A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms. Neurobiology of Aging, 2018, 72, 189.e11-189.e17.	3.1	3
148	Multicenter validation of [¹⁸F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 570-577.	1.7	19
149	Genetic counselling: Psychological impact and concerns. , 2018, , .		1
150	Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study. BMJ Supportive and Palliative Care, 2017, 7, 164-172.	1.6	106
151	Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDPâ€43 subcellular distribution. Neuropathology and Applied Neurobiology, 2017, 43, 133-153.	3.2	23
152	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	10.2	62
153	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.1-281.	1.9	33
154	The changing picture of amyotrophic lateral sclerosis: lessons from European registers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 557-563.	1.9	89
155	Incidence of amyotrophic lateral sclerosis in the province of Novara, Italy, and possible role of environmental pollution. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 284-290.	1.7	21
156	C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration?. Journal of the Neurological Sciences, 2017, 378, 49-51.	0.6	5
157	Use of Genetic Testing in Amyotrophic Lateral Sclerosis by Neurologists. JAMA Neurology, 2017, 74, 125.	9.0	15
158	Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 590-597.	1.7	27
159	Occupations and amyotrophic lateral sclerosis: are jobs exposed to the general public at higher risk?. European Journal of Public Health, 2017, 27, 643-647.	0.3	7
160	Age-related penetrance of the C9orf72 repeat expansion. Scientific Reports, 2017, 7, 2116.	3.3	102
161	Amyotrophic lateral sclerosis. Lancet, The, 2017, 390, 2084-2098.	13.7	867
162	A20 in Multiple Sclerosis and Parkinsonâ€™s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. Neurotoxicity Research, 2017, 32, 1-7.	2.7	23

#	Article	IF	Citations
163	Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 660.	9.0	96
164	Critical issues in ALS case-control studies: the case of the Euro-MOTOR study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 411-418.	1.7	16
165	Pain in amyotrophic lateral sclerosis. Lancet Neurology, The, 2017, 16, 144-157.	10.2	97
166	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	30.5	885
167	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
168	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 2017, 89, 1915-1922.	1.1	82
169	A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology, 2017, 89, 1283-1290.	1.1	48
170	Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. Journal of Neurology, 2017, 264, 2224-2231.	3.6	19
171	Multimodal structural MRI in the diagnosis of motor neuron diseases. NeuroImage: Clinical, 2017, 16, 240-247.	2.7	55
172	NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?. Free Radical Biology and Medicine, 2017, 112, 387-396.	2.9	88
173	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open, 2017, 7, e015434.	1.9	14
174	Genetic screening in sporadic ALS and FTD. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1042-1044.	1.9	105
175	Secular Trends of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 1097.	9.0	85
176	Factors predicting survival in ALS: a multicenter Italian study. Journal of Neurology, 2017, 264, 54-63.	3.6	96
177	Acoustic reflex patterns in amyotrophic lateral sclerosis. European Archives of Oto-Rhino-Laryngology, 2017, 274, 679-683.	1.6	5
178	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2017, 10, 99.	2.9	30
179	Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype. Frontiers in Molecular Neuroscience, 2017, 10, 370.	2.9	24
180	C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. Human Molecular Genetics, 2017, 26, 1133-1145.	2.9	23

#	Article	IF	Citations
181	Structural brain correlates of cognitive and behavioral impairment in <scp>MND</scp>. Human Brain Mapping, 2016, 37, 1614-1626.	3.6	84
182	Influence of cigarette smoking on ALS outcome: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1229-1233.	1.9	37
183	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	3.1	40
184	Curable or treatable? The implications of different definitions of illness when treating patients suffering from amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 15-20.	1.7	5
185	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 325-336.	1.7	14
186	The quest for exogenous risk factors in ALS: Is there a place for physical activity?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 311-312.	1.7	0
187	Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?. Cytotherapy, 2016, 18, 1471-1475.	0.7	21
188	Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1. Human Mutation, 2016, 37, 1202-1208.	2.5	45
189	Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System. Neuroepidemiology, 2016, 47, 59-66.	2.3	16
190	Genetics of multiple system atrophy. Neurology, 2016, 87, 1530-1531.	1.1	0
191	Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurology, The, 2016, 15, 1182-1194.	10.2	301
192	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	6.4	27
193	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
194	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218
195	Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communications, 2016, 7, 12408.	12.8	290
196	<scp>NADPH</scp> oxidase 2 (<scp>NOX</scp>2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 2016, 23, 958-963.	3.3	13
197	Association of a Locus in theCAMTA1Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
198	Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Human Brain Mapping, 2016, 37, 942-953.	3.6	40

#	Article	IF	Citations
199	Novel Compound Heterozygous Spatacsin Mutations in a Greek Kindred with Hereditary Spastic Paraplegia SPG11 and Dementia. Neurodegenerative Diseases, 2016, 16, 373-381.	1.4	11
200	ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion. Neurobiology of Aging, 2016, 39, 218.e5-218.e8.	3.1	6
201	Degenerative neuromuscular diseases: crucial gene and cell machinery discoveries. Lancet Neurology, The, 2016, 15, 12-13.	10.2	1
202	A new scale for prognostication in Parkinson disease. Neurology, 2016, 86, 982-983.	1.1	2
203	The Role ofAPOEin the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 425.	9.0	37
204	Systems biology analysis of the proteomic alterations in Parkinson's disease: Common and disease-specific pathways. Parkinsonism and Related Disorders, 2016, 22, e173-e174.	2.2	0
205	Professor Camillo Negroâ€™s Neuropathological Films. Journal of the History of the Neurosciences, 2016, 25, 39-50.	0.9	9
206	Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 245-248.	1.7	6
207	¹⁸ F-FDG-PET correlates of cognitive impairment in ALS. Neurology, 2016, 86, 44-49.	1.1	84
208	Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 77-84.	1.7	9
209	Alcohol and amyotrophic lateral sclerosis: a possible neuroprotective effect. European Journal of Neurology, 2016, 23, 221-222.	3.3	2
210	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 841-854.	2.2	14
211	The palliative care needs of people severely affected by neurodegenerative disorders: A qualitative study. Progress in Palliative Care, 2015, 23, 331-342.	1.2	20
212	A Multicentric Prospective Incidence Study of Guillain-BarrÃ© Syndrome in Italy. The ITANG Study. Neuroepidemiology, 2015, 45, 90-99.	2.3	27
213	ALS mutant FUS proteins are recruited into stress granules in induced Pluripotent Stem Cells (iPSCs) derived motoneurons. DMM Disease Models and Mechanisms, 2015, 8, 755-66.	2.4	121
214	Biomarkers for ALSâ€”in search of the Promised Land. Nature Reviews Neurology, 2015, 11, 72-74.	10.1	22
215	Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 8-15.	1.7	10
216	HFE p.H63D polymorphism does not influence ALS phenotype and survival. Neurobiology of Aging, 2015, 36, 2906.e7-2906.e11.	3.1	8

#	Article	IF	Citations
217	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 879-886.	1.9	32
218	Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 274-276.	1.7	3
219	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
220	The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1180-1185.	1.9	42
221	Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. Journal of Neurology, 2015, 262, 375-384.	3.6	50
222	Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of Neurology, 2015, 262, 1447-1454.	3.6	84
223	CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2015, 36, 1767.e3-1767.e6.	3.1	44
224	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
225	MRI signatures of the frontotemporal lobar degeneration continuum. Human Brain Mapping, 2015, 36, 2602-2614.	3.6	39
226	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	3.1	19
227	Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. Journal of Neurology, 2015, 262, 2662-2667.	3.6	14
228	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinsonâ€™s disease complicated by psychosis or dementia in a Sardinian population. Journal of Neurology, 2015, 262, 2498-2503.	3.6	25
229	Disorders of Upper and Lower Motor Neurons. , 2015, , 261-272.		2
230	Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 129-130.	1.7	5
231	ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology, 2015, 84, 251-258.	1.1	52
232	Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 38-44.	1.9	160
233	Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 168-173.	1.9	233
234	A novel p.E121G heterozygous missense mutation of SOD1 in an apparently sporadic ALS case with a 14-year course. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 127-128.	1.7	6

#	Article	IF	Citations
235	Sclerosi laterale amiotrofica come modello di gestione interdisciplinare. Salute E Societa, 2015, , 173-184.	0.1	1
236	Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 98-105.	1.7	54
237	Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology, 2014, 83, 1067-1074.	1.1	154
238	The last months of life of people with amyotrophic lateral sclerosis in mechanical invasive ventilation: A qualitative study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 499-504.	1.7	31
239	Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 1123.	9.0	69
240	Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine. JAMA Neurology, 2014, 71, 1134.	9.0	150
241	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
242	The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 844-852.	6.4	103
243	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	14.8	398
244	A familial ALS case carrying a novel p.G147CSOD1heterozygous missense mutation with non-executive cognitive impairment: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1437-1439.	1.9	11
245	Genetic counselling in ALS: facts, uncertainties and clinical suggestions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 478-485.	1.9	99
246	State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 2014, 17, 17-23.	14.8	1,300
247	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 2220-2231.	2.9	123
248	Resting state functional connectivity alterations in primary lateral sclerosis. Neurobiology of Aging, 2014, 35, 916-925.	3.1	41
249	Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurology, The, 2014, 13, 1108-1113.	10.2	302
250	Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurology, The, 2014, 13, 1228-1240.	10.2	201
251	Genetic architecture of ALS in Sardinia. Neurobiology of Aging, 2014, 35, 2882.e7-2882.e12.	3.1	60
252	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 1916-1922.	2.9	23

#	Article	IF	Citations
253	Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain, 2014, 137, e311-e311.	7.6	112
254	NADPH oxidase (NOX2) activity is a modifier of survival in ALS. Journal of Neurology, 2014, 261, 2178-2183.	3.6	36
255	Physical activity and amyotrophic lateral sclerosis: A European populationâ€based caseâ€“control study. Annals of Neurology, 2014, 75, 708-716.	5.3	79
256	<scp>C9orf72</scp> and <scp>UNC13A</scp> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genomeâ€wide metaâ€analysis. Annals of Neurology, 2014, 76, 120-133.	5.3	91
257	Reduced cellular Ca2+ availability enhances TDP-43 cleavage by apoptotic caspases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 725-734.	4.1	17
258	A de novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. Neurobiology of Aging, 2014, 35, 1513.e7-1513.e11.	3.1	21
259	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. Human Brain Mapping, 2014, 35, 1710-1722.	3.6	76
260	Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?. Journal of Neurology, 2013, 260, 1155-1157.	3.6	38
261	Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995â€“2009. Journal of Neurology, 2013, 260, 572-579.	3.6	40
262	Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1340-1345.	1.9	126
263	Risk of Guillain-BarrÃ© syndrome after 2010â€“2011 influenza vaccination. European Journal of Epidemiology, 2013, 28, 433-444.	5.7	41
264	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. Neurogenetics, 2013, 14, 161-166.	1.4	38
265	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
266	UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiology of Aging, 2013, 34, 357.e1-357.e5.	3.1	59
267	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiology of Aging, 2013, 34, 357.e7-357.e19.	3.1	69
268	The final chapter of the ALS lithium saga. Lancet Neurology, The, 2013, 12, 324-325.	10.2	12
269	Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 452-456.	1.7	2
270	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.7	68

#	Article	IF	Citations
271	Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels. Neuron, 2013, 78, 57-64.	8.1	127
272	Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology, 2013, 41, 118-130.	2.3	659
273	Homozygosity analysis in amyotrophic lateral sclerosis. European Journal of Human Genetics, 2013, 21, 1429-1435.	2.8	12
274	Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 33-43.	1.7	33
275	Amyotrophic lateral sclerosis in Piedmont (Italy): A Bayesian spatial analysis of the incident cases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 58-65.	1.7	21
276	Extramotor Damage Is Associated with Cognition in Primary Lateral Sclerosis Patients. PLoS ONE, 2013, 8, e82017.	2.5	33
277	Physical fitness and amyotrophic lateral sclerosis: dangerous liaisons or common genetic pathways?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 389-389.	1.9	11
278	Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 377-381.	1.9	73
279	Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology, 2012, 78, 1085-1089.	1.1	67
280	SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology, 2012, 79, 1556-1562.	1.1	252
281	A Distinct MR Imaging Phenotype in Amyotrophic Lateral Sclerosis: Correlation between T1 Magnetization Transfer Contrast Hyperintensity along the Corticospinal Tract and Diffusion Tensor Imaging Analysis. American Journal of Neuroradiology, 2012, 33, 733-739.	2.4	25
282	An ALS case with a novel D90N-SOD1 heterozygous missense mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 393-395.	2.1	3
283	Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype?. Journal of Neurology, 2012, 259, 1749-1751.	3.6	49
284	Extensive genetics of ALS. Neurology, 2012, 79, 1983-1989.	1.1	145
285	Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessiveâ€“compulsive disorder associated to GGGGCC expansion of the c9orf72 gene. Journal of Neurology, 2012, 259, 2723-2725.	3.6	37
286	Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: The Italian multicentre study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 580-584.	2.1	7
287	ALS/FTD phenotype in two Sardinian families carrying bothC9ORF72andTARDBPmutations. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 730-733.	1.9	57
288	Mutational analysis of the VCP gene in Parkinson's disease. Neurobiology of Aging, 2012, 33, 209.e1-209.e2.	3.1	31

#	Article	IF	Citations
289	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	3.1	115
290	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	3.1	76
291	Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2231.e1-2231.e6.	3.1	86
292	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	7.6	182
293	Cognitive screening in patients with amyotrophic lateral sclerosis in early stages. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 95-101.	2.1	26
294	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
295	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) â€“ revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
296	Pain in amyotrophic lateral sclerosis: a populationâ€based controlled study. European Journal of Neurology, 2012, 19, 551-555.	3.3	81
297	Trauma and amyotrophic lateral sclerosis: a caseâ€“control study from a populationâ€based registry. European Journal of Neurology, 2012, 19, 1509-1517.	3.3	63
298	Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 251-259.	6.4	148
299	Prospective epidemiological registers: a valuable tool for uncovering ALS pathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1066-1066.	1.9	3
300	Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 740-746.	1.9	513
301	FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 550.e1-550.e4.	3.1	79
302	A de novo missense mutation of the FUS gene in a â€œtrueâ€•sporadic ALS case. Neurobiology of Aging, 2011, 32, 553.e23-553.e26.	3.1	58
303	A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiology of Aging, 2011, 32, 2327.e1-2327.e5.	3.1	43
304	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2011, 69, 397.	8.1	7
305	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
306	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10.	2.1	107

#	Article	IF	Citations
307	Identifying potential risk factors for developing amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2011, 1, 463-471.	2.2	6
308	Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene. Archives of Neurology, 2011, 68, 594.	4.5	104
309	Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathologica, 2011, 121, 611-622.	7.7	56
310	Repeated courses of granulocyte colonyâ€stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle and Nerve, 2011, 43, 189-195.	2.2	64
311	Monomelic amyotrophy is not always benign: A case report. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 307-308.	2.1	6
312	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	3.4	50
313	ALS clinical trials. Neurology, 2011, 77, 1432-1437.	1.1	96
314	Religiousness is positively associated with quality of life of ALS caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 168-171.	2.1	24
315	Neuropathology of Olfactory Ensheathing Cell Transplantation into the Brain of Two Amyotrophic Lateral Sclerosis (ALS) Patients. Brain Pathology, 2010, 20, 730-737.	4.1	25
316	Amyotrophic Lateral Sclerosisâ€“Frontotemporal Lobar Dementia in 3 Families With p.Ala382Thr TARDBP Mutations. Archives of Neurology, 2010, 67, 1002-9.	4.5	53
317	Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 385-390.	1.9	648
318	Amyotrophic lateral sclerosis mimic syndrome due to a dorsal spinal cord neurofibroma. Neurological Sciences, 2010, 31, 111-113.	1.9	0
319	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology, The, 2010, 9, 986-994.	10.2	205
320	Neurobehavioral symptoms in ALS are negatively related to caregiversâ€™ burden and quality of life. European Journal of Neurology, 2010, 17, 1298-1303.	3.3	126
321	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.1	90
322	Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12335-12338.	7.1	29
323	LOWER SERUM LIPID LEVELS ARE RELATED TO RESPIRATORY IMPAIRMENT IN PATIENTS WITH ALS. Neurology, 2010, 74, 2027-2028.	1.1	5
324	Tau levels do not influence human ALS or motor neuron degeneration in the SOD1 ^{G93A} mouse. Neurology, 2010, 74, 1687-1693.	1.1	18

#	Article	IF	Citations
325	The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis. American Journal of Neuroradiology, 2010, 31, 1769-1777.	2.4	124
326	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2010, 68, 857-864.	8.1	1,100
327	Amyotrophic lateral sclerosis, physical exercise, trauma and sports: Results of a population-based pilot case-control study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 289-292.	2.1	110
328	Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1141-1143.	1.9	89
329	Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 38-45.	2.1	293
330	Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyteâ€“colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy, 2010, 12, 50-59.	0.7	36
331	Quality of Life and Depression in Patient-Giver Scenarios: Reference to Amyotrophic Lateral Sclerosis. , 2010, , 3511-3539.		1
332	Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?. CNS and Neurological Disorders - Drug Targets, 2010, 9, 325-330.	1.4	32
333	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, 1524-1532.	2.9	106
334	Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology, 2009, 73, 1681-1685.	1.1	142
335	Epidemiology of ALS in Italy. Neurology, 2009, 72, 725-731.	1.1	237
336	Understanding users and their needs. Universal Access in the Information Society, 2009, 8, 259-275.	3.0	39
337	Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurologica Scandinavica, 2009, 119, 126-130.	2.1	51
338	Comorbidity between CIDP and diabetes mellitus: only a matter of chance?. European Journal of Neurology, 2009, 16, 752-754.	3.3	28
339	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 310-323.	2.1	839
340	Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. Neurobiology of Aging, 2009, 30, 1272-1275.	3.1	128
341	ALS in Italian professional soccer players: The risk is still present and could be soccer-specific. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 205-209.	2.1	144
342	Sclerosi laterale amiotrofica e atrofie muscolari spinali. , 2009, , 427-436.		0

#	Article	IF	Citations
343	MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics and Proteomics, 2009, 6, 219-27.	2.0	24
344	Anxiety undermines quality of life in ALS patients and caregivers. European Journal of Neurology, 2008, 15, 1231-1236.	3.3	73
345	Amyotrophic lateral sclerosis and soccer: A different epidemiological approach strengthen the previous findings. Journal of the Neurological Sciences, 2008, 269, 187-188.	0.6	12
346	The rare G93D mutation causes a slowly progressing lower motor neuron disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 35-39.	2.1	18
347	Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 6-11.	1.9	364
348	Prevalence of SOD1 mutations in the Italian ALS population. Neurology, 2008, 70, 533-537.	1.1	118
349	Eye Tracking Impact on Quality-of-Life of ALS Patients. Lecture Notes in Computer Science, 2008, , 70-77.	1.3	32
350	A longitudinal study on quality of life and depression in ALS patientâ€“caregiver couples. Neurology, 2007, 68, 923-926.	1.1	215
351	The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. Current Medicinal Chemistry, 2007, 14, 3185-3200.	2.4	62
352	EFFECT OF REFERRAL BIAS ON ASSESSING SURVIVAL IN ALS. Neurology, 2007, 69, 939-940.	1.1	14
353	Phase II/III randomized trial of TCH346 in patients with ALS. Neurology, 2007, 69, 776-784.	1.1	112
354	Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1349-1353.	1.9	128
355	ALS patients and caregivers communication preferences and information seeking behaviour. European Journal of Neurology, 2007, 15, 071116221701004-???.	3.3	42
356	Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurology, The, 2007, 6, 322-328.	10.2	206
357	Repeated Courses of Bone Marrow-Derived Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor (G-CSF) in Amyotrophic Lateral Sclerosis: Interim Analysis of a Prospective Multicenter Trial.. Blood, 2007, 110, 4065-4065.	1.4	1
358	The epidemiology of ALS and the role of population-based registries. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1150-1157.	3.8	168
359	Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. NeuroToxicology, 2006, 27, 333-339.	3.0	94
360	Treatment response and electrophysiological criteria in chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 2006, 13, 669-670.	3.3	8

#	Article	IF	Citations
361	Analysis of IFT74as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurology, 2006, 6, 44.	1.8	70
362	Caregiver time use in ALS. Neurology, 2006, 67, 902-904.	1.1	68
363	HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 327-327.	1.9	36
364	Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 754-756.	1.9	118
365	Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 948-950.	1.9	188
366	Anaplasia Is Rare and Does Not Influence Prognosis in Adult Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2005, 64, 869-874.	1.7	22
367	Mortality trends in ALS: an increasingly intricate puzzle. Lancet Neurology, The, 2005, 4, 453-454.	10.2	12
368	Caregiver burden and patients' perception of being a burden in ALS. Neurology, 2005, 64, 1780-1782.	1.1	191
369	Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 17-28.	2.1	71
370	Cogwheel Rigidity. Archives of Neurology, 2005, 62, 828.	4.5	14
371	Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 2005, 128, 472-476.	7.6	386
372	The IVS1 +319 t>a of SOD1 gene is not an ALS causing mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 45-49.	2.1	10
373	A cross sectional study on determinants of quality of life in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1597-1601.	1.9	152
374	Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 645-647.	1.9	124
375	Motor neuron disease and optic neuropathy after acute exposure to a methanolâ€containing solvent mixture. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 188-191.	1.2	7
376	Breaking the news in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 195-201.	1.2	39
377	Randomised controlled trial in non-invasive ventilation: what trial?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 255-256.	1.2	10
378	Activity of protein phosphatase calcineurin is decreased in sporadic and familial amyotrophic lateral sclerosispatients. Journal of Neurochemistry, 2004, 90, 1237-1242.	3.9	34

#	Article	IF	Citations
379	Risk of cancer in patients with Guillain-Barrï¿½ syndrome (GBS). Journal of Neurology, 2004, 251, 321-326.	3.6	86
380	Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: recent findings and achievements from a network of laboratories. Neurological Sciences, 2004, 25, s41-s60.	1.9	16
381	Disease penetrance in amyotrophic lateral sclerosis associated with mutations in the SOD1 gene. Annals of Neurology, 2004, 55, 298-299.	5.3	22
382	Cesare Lombroso, cortical dysplasia, and epilepsy: Keen findings and odd theories. Neurology, 2004, 63, 194-194.	1.1	6
383	Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. Journal of Neuro-Oncology, 2003, 61, 95-102.	2.9	20
384	The sinister side of Italian soccer. Lancet Neurology, The, 2003, 2, 656-657.	10.2	46
385	Guillain-Barrel•syndrome. Neurology, 2003, 60, 1146-1150.	1.1	214
386	Prognosis in amyotrophic lateral sclerosis: A population-based study. Neurology, 2003, 61, 1826-1827.	1.1	6
387	Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology, 2003, 60, 1560-1561.	1.1	2
388	Cesare Lombroso, cortical dysplasia, and epilepsy. Neurology, 2003, 61, 1412-1416.	1.1	15
389	Amyotrophic lateral sclerosis associated with pregnancy: report of four new cases and review of the literature. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 45-48.	1.2	22
390	Arthur Van Gehuchten takes neurology to the movies. Neurology, 2003, 61, 587-588.	1.1	9
391	Amyotrophic lateral sclerosis associated with pregnancy: report of four new cases and review of the literature. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 45-48.	1.2	0
392	Early symptom progression rate is related to ALS outcome. Neurology, 2002, 59, 99-103.	1.1	232
393	Early symptom progression rate is related to ALS outcome: A prospective population-based study. Neurology, 2002, 59, 2012-2013.	1.1	8
394	Reliability of the El Escorial Diagnostic Criteria for Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2002, 21, 265-270.	2.3	58
395	Validity of hospital morbidity records for amyotrophic lateral sclerosis. Journal of Clinical Epidemiology, 2002, 55, 723-727.	5.0	46
396	MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro-Oncology, 2002, 4, 115-122.	1.2	4

#	Article	IF	Citations
397	Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. Journal of the Neurological Sciences, 2001, 191, 145-150.	0.6	50
398	Validity of hospital discharge diagnoses for the assessment of the prevalence and incidence of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 99-104.	1.2	31
399	Conjugal amyotrophic lateral sclerosis: suggestion for the implication of environmental factors. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 165-166.	1.2	8
400	CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. International Journal of Cancer, 2000, 88, 554-557.	5.1	53
401	Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2000, 247, 778-782.	3.6	30
402	A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology, 2000, 54, 469-469.	1.1	38
403	Editorial and Guest Editorials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 139-141.	1.2	0
404	Update on ISIS survey: Europe, North America and South America. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S9-S11.	1.2	11
405	Risk factors in the early diagnosis of ALS: European epidemiological studies. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S13-S18.	1.2	34
406	The prognostic role of vessel productive changes and vessel density in oligodendroglioma. Journal of Neuro-Oncology, 1999, 44, 99-107.	2.9	28
407	Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. Journal of Neurology, 1999, 246, 175-180.	3.6	28
408	ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. Journal of Neurology, 1999, 246, III1-III5.	3.6	98
409	p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathologica, 1999, 98, 629-634.	7.7	32
410	Epidemiology of adult medulloblastoma. International Journal of Cancer, 1999, 80, 689-692.	5.1	97
411	Epidemiology of adult medulloblastoma. , 1999, 80, 689.		1
412	Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology, 1999, 53, 1123-1123.	1.1	116
413	ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. Journal of Neurology, 1999, 246, s001-s005.	3.6	0
414	Prevalence of Parkinson's disease in northwestern italy: Comparison of tracer methodology and clinical ascertainment of cases. Movement Disorders, 1998, 13, 400-405.	3.9	78

#	Article	IF	Citations
415	Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Italian Journal of Neurological Sciences, 1998, 19, 363-366.	0.1	31
416	Prognostic Factors in Oligodendroglioma. Canadian Journal of Neurological Sciences, 1997, 24, 313-319.	0.5	85
417	Lamotrigine reduces total postoperative analgesic requirement: A randomized double-blind, placebo-controlled pilot study. Surgery, 1997, 122, 567-570.	1.9	40
418	Role of apoptosis in the prognosis of oligodendrogliomas. Neurochemistry International, 1997, 31, 245-250.	3.8	25
419	Proliferative activity and prognosis of low-grade astrocytomas. Journal of Neuro-Oncology, 1997, 34, 31-35.	2.9	53
420	Is medulloblastoma the same tumor in children and adults?. Journal of Neuro-Oncology, 1997, 35, 169-176.	2.9	46
421	Ceftriaxone in amyotrophic lateral sclerosis. European Journal of Neurology, 1996, 3, 295-298.	3.3	5
422	Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study. Tumori, 1995, 81, 338-346.	1.1	35
423	Apoptosis and cell proliferation in human neuroepithelial tumors. Neuroscience Letters, 1995, 195, 81-84.	2.1	91
424	The increase of Parkinson's disease mortality could be due to a cohort effect. Acta Neurologica Scandinavica, 1995, 92, 113-115.	2.1	4
425	Gompertzian Analysis of Amyotrophic Lateral Sclerosis Mortality in Italy, 1957â€“1987; Application to Birth Cohorts. Neuroepidemiology, 1995, 14, 269-277.	2.3	17
426	Prognostic factors in adult medulloblastoma. A clinico-pathologic study. Tumori, 1995, 81, 338-46.	1.1	13
427	Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance. Tumori, 1994, 80, 295-300.	1.1	20
428	Fourth meeting of the European Neurological Society 25â€“29 June 1994 Barcelona, Spain. Journal of Neurology, 1994, 241, 1-164.	3.6	20
429	Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathologica, 1994, 87, 362-370.	7.7	63
430	Ubiquitinated dystrophic neurites suggest corticospinal derangement in patients with amyotrophic lateral sclerosis. Neuroscience Letters, 1994, 180, 21-24.	2.1	16
431	Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: its prognostic significance. Tumori, 1994, 80, 295-300.	1.1	5
432	Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathologica, 1993, 85, 495-502.	7.7	41

#	Article	IF	Citations
433	Early onset cerebellar ataxia with retained tendon reflexes: prevalence and gene frequency in an Italian population. Clinical Genetics, 1993, 43, 207-2011.	2.0	21
434	Reduced life expectancy in 40 cases of early onset cerebellar ataxia with retained tendon reflexes: a population-based study. Acta Neurologica Scandinavica, 1993, 88, 358-362.	2.1	2
435	Parkinson's Disease Mortality in Italy, 1951 Through 1987. Archives of Neurology, 1993, 50, 149.	4.5	15
436	PATHOLOGY OF THE UPPER MOTOR NEURON IN ALS. Journal of Neuropathology and Experimental Neurology, 1993, 52, 279.	1.7	2
437	USEFULNESS OF Ki-67, CLONE MIB-1, AS A PROGNOSTIC FACTOR IN EPENDYMOMAS. Journal of Neuropathology and Experimental Neurology, 1993, 52, 324.	1.7	1
438	Amyotrophic lateral sclerosis mortality in Italy, 1958 to 1987. Neurology, 1993, 43, 927-927.	1.1	29
439	Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis.. Journal of Epidemiology and Community Health, 1992, 46, 517-518.	3.7	60
440	Ubiquitin in Motor Neuron Disease. Journal of Neuropathology and Experimental Neurology, 1991, 50, 463-473.	1.7	67
441	Ependymoma: Internal Correlations among Pathological Signs: The Anaplastic Variant. Neurosurgery, 1991, 29, 206-210.	1.1	82
442	Risk Factors in Motor Neuron Disease: A Case-Control Study. Neuroepidemiology, 1991, 10, 174-184.	2.3	93
443	Histologic prognostic factors in ependymoma. Child's Nervous System, 1991, 7, 177-82.	1.1	138
444	Trends in Parkinson's Disease Mortality in Italy. Archives of Neurology, 1991, 48, 1010-1011.	4.5	0
445	Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery, 1991, 29, 206-10.	1.1	23
446	Vascular response to irradiation in malignant gliomas. Journal of Neuro-Oncology, 1990, 8, 73-84.	2.9	7
447	IMMUNOHISTOCHEMISTRY AND IMMUNOELECTRON MICROSCOPY OF UBIQUITIN IN ALS. Journal of Neuropathology and Experimental Neurology, 1990, 49, 277.	1.7	1
448	Epidemiology of Motor Neuron Disease in Two Italian Provinces. Neuroepidemiology, 1989, 8, 79-86.	2.3	7
449	The vascular response to tumor infiltration in malignant gliomas. Acta Neuropathologica, 1989, 77, 369-378.	7.7	52
450	MOTONEURON DISEASE AND SOLVENT AND GLUE EXPOSURE. Lancet, The, 1989, 334, 921.	13.7	3

#	Article	IF	Citations
451	Prognostic Factors in Well-Differentiated Cerebral Astrocytomas in the Adult. Neurosurgery, 1989, 24, 686-692.	1.1	207
452	Glutamate dehydrogenase (GDH) deficiency in different types of progressive hereditary cerebellar ataxia. Acta Neurologica Scandinavica, 1988, 78, 394-400.	2.1	7
453	Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer, 1988, 61, 1386-1393.	4.1	49
454	A follow-up study of 60 cases of chronic spinal muscular atrophy. Italian Journal of Neurological Sciences, 1988, 9, 47-51.	0.1	3
455	Motor neuron disease and malignancies: results of a population-based study. Journal of Neurology, 1988, 235, 374-375.	3.6	31
456	Post-Poliomyelitic Motor Neuron Disease. European Neurology, 1988, 28, 177-180.	1.4	1
457	Primary Lymphomas of the Brain: A Clinico-Pathologic Review of 37 Cases. Tumori, 1987, 73, 585-592.	1.1	17
458	Hereditary motor and sensory neuropathies: A genetic and epidemiological study in the province of Turin, Italy. Italian Journal of Neurological Sciences, 1987, 8, 369-374.	0.1	4
459	Phenotypic and genotypic heterogeneity of dominantly inherited amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 1987, 75, 277-282.	2.1	23
460	A Study of Prognostic Factors in Motor Neuron Disease. , 1987, 209, 255-263.		11
461	Clinical-anatomic study of a family with bulbo-spinal muscular atrophy in adults. Journal of the Neurological Sciences, 1986, 73, 11-22.	0.6	8
462	A survival analysis of 155 cases of progressive muscular atrophy. Acta Neurologica Scandinavica, 1985, 72, 407-413.	2.1	25
463	Motor neuron disease in the province of Turin, Italy, 1966â€“1980. Journal of the Neurological Sciences, 1984, 66, 165-173.	0.6	38
464	Motor neuron disease in the Province of Turin, Italy, 1971-1980. Acta Neurologica Scandinavica, 1983, 68, 316-327.	2.1	28
465	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-14.	2.1	16
466	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
467	Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations. Frontiers in Neurology, 0, 13, .	2.4	5